Dianthus Therapeutics Inc
DNTH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.17B
Close$
$-2.20
102.4% downside
Current Fair Value
102.4% downsideOvervalued by 102.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.17 Billion |
|---|---|
| Enterprise Value | $5.12 Billion |
| Earnings per Share | $-4.2 |
| Beta | 0.08 |
| Outstanding Shares | 57,341,193 |
Return
| Return on Equity | -3.20% |
|---|---|
| Return on Assets | -3.12% |
| Return on Invested Capital | -17.07% |
Valuation & Multiples
| P/E Ratio | 3060.33 |
|---|---|
| PEG | 11390.28 |
| Price to Sales | - |
| Price to Book Ratio | 4.37 |
| Enterprise Value to Revenue | 2269.26 |
| Enterprise Value to EBIT | -24.03 |
| Enterprise Value to Net Income | -129 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
-$0.94
Consensus analyst estimateRevenue Estimate
$460,928
Consensus analyst estimateNext Earnings Call
Expected Date
March 8, 2027
EPS Estimate
-$0.96
Consensus analyst estimateRevenue Estimate
$447,591
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.01, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0058▼ 92.70% |
|---|---|
| Total Calls | 86,900▼ 65.41% |
| Total Puts | 500▼ 99.79% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.70%▼ 128.96% |
|---|---|
| Total Invested | $429.50M▼ 93.33% |
| Investors Holding | 80▼ 199.00% |
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...